• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

27 April 2019

FDA approves Benlysta (belimumab) first treatment for pediatric patients with lupus


0 Comments3 Minutes

17 April 2019

Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients


0 Comments9 Minutes

9 April 2019

Dovato (dolutegravir and lamivudine), a new complete regimen for HIV-infected patients who have never received antiretroviral treatment


0 Comments5 Minutes

3 April 2019

Mayzent (siponimod) tablets approved by FDA to treat adults with relapsing forms of multiple sclerosis (MS)


0 Comments5 Minutes

2 April 2019

Zynteglo, New gene therapy to treat rare inherited blood condition


0 Comments4 Minutes

1 April 2019

Merck has announced the FDA approval of its Mavenclad (cladribine) tablets in various forms of multiple sclerosis (MS).


0 Comments5 Minutes

12 March 2019

FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic


0 Comments6 Minutes

4 March 2019

New indication for Dupixent (dupilumab) as add on treatment for patients with severe asthma


0 Comments3 Minutes

4 March 2019

Ondexxya (andexanet alfa), first antidote for reversal of anticoagulation with factor Xa inhibitors apixaban and rivaroxaban


0 Comments3 Minutes

4 March 2019

Waylivra (volanesorsen), first treatment for rare disease characterised by high levels of triglycerides in blood


0 Comments3 Minutes

  • 1
  • …
  • 10
  • 11
  • 12
  • 13

Warning:

A cybersecurity incident is under investigation. Please be carefull with emails or phone calls that correctly mention your name, role, or current transactions. Elixi’s crisis team is working to limit any harmful impact, as the security of our clients’ and suppliers’ data is Elixi’s top priority. For any clarification, you can contact: DPO@elixi-int.com

Si è verificato un evento di sicurezza informatica in corso di analisi. Vi invitiamo a prestare massima attenzione messaggi di posta elettronica o telefonate che citano correttamente il vostro nome, la funzione o operazioni realmente avvenute. Il crisis team di Elixi sta lavorando per limitare ogni conseguenza dannosa, perchè la sicurezza dei dati dei nostri clienti e dei fornitori è la nostra priorità di Elixi. Per ogni chiarimento potete contattare: DPO@elixi-int.com